WOONSOCKET, R.I., May 31, 2011 /PRNewswire/ — MultiCell
Technologies, Inc. (OTC Bulletin Board:
MCET) is pleased to announce the issuance of U.S. patent
7,935,528 by the United States Patent and Trademark Office (USPTO)
relating to the isolation and use of human liver stem cells to
treat liver disease. Under the terms of its license agreement
with Rhode Island Hospital, MultiCell Technologies is the worldwide
exclusive licensee of U.S. patent 7,935,528.
The patent describes methods to isolate and use human liver stem
cells to treat degenerative liver diseases, or inherited
deficiencies of liver function. Patients who suffer from
severe, irreversible liver disease for which other medical and
surgical treatments have failed are often candidates for a liver
transplant. Liver stem cells which differentiate into
functional mature hepatocytes could help to reconstitute a diseased
liver, and may be an alternative approach to whole organ
transplants for certain liver diseases.
“We are pleased the USPTO has agreed that our liver stem cells
are indeed novel and may lead to important therapeutic
applications,” said W. Gerald Newmin, Chairman and Chief Executive
Officer. “Our efforts to better understand liver stem cell
biology, and the role these cells play in chronic liver disease and
primary hepatocellular carcinoma, is a major focus of the Company,”
Mr. Newmin stated.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage
biopharmaceutical company developing novel therapeutics and
discovery tools that address unmet medical needs for the treatment
of neurological disorders, hepatic disease and cancer. For
more information about MultiCell Technologies, please visit http://www.multicelltech.com.
Caution Regarding Forward-Looking Statements